Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Jan 16, 2024 1:43pm
186 Views
Post# 35829533

RE:RE:RE:RE:Improving results yet

RE:RE:RE:RE:Improving results yet
I've never really minded how they project the timeline for full FDA approval as that is the only way that the can do it and be honest. They would get in trouble to predict anything faster or to predict accellerated approval. I think they would be a very good candidate for AA.

By way of example, it seems like most drugs take 2-3 years from AA to get final approval. But the great thing about AA is that they can sell the drug in the meantime.

A recent example is interesting. Takeda had AA for Mobocertinib for NSCLC back in Sept 2021. They started selling and sales may have been quite good. However, once the full patient numbers were reported, it turned out that they didn't have the evidence that the drug was better. It was withdrawn in Oct 2023.

I see TLT as needing the full 18 m data set on 100 patients to get final FDA approval. But if you have good statistical support  you can get AA much sooner showing that the data is looking good. For example, if they chase down the 18 m data and find that all 450 day CR's stayed CR then you could make a statistical case that you will soon have enough info for AA based on durable response part. 

Better yet, I've said before that all 4 in a row CRs (green from 90 to 360) stay CR to 450 with no conversion to IR or NR, so it would be cool if that held true for the 18 m follow up. In which case, you could make a statistical case that 360 day follow up is enought to confirm durable CR. 360 become the new 540 :)

Again I'm talking the continous CR patients for the above example. The green all the way across ones.
<< Previous
Bullboard Posts
Next >>